OTCMKTS:MRVFF Nuvo Pharmaceuticals (MRVFF) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MRVFF Stock Alerts $0.98 0.00 (0.00%) (As of 03/16/2023) Add Compare Share Share Today's Range$0.98▼$0.9850-Day Range$0.98▼$0.9852-Week Range$0.42▼$1.25VolumeN/AAverage Volume11,250 shsMarket Capitalization$11.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nuvo Pharmaceuticals alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Nuvo Pharmaceuticals Stock (OTCMKTS:MRVFF)Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Read More MRVFF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVFF Stock News HeadlinesFebruary 2, 2024 | morningstar.comWest Pharmaceutical Services Inc WSTAugust 1, 2023 | seekingalpha.comNYMXF Nymox Pharmaceutical CorporationApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 10, 2023 | businesswire.comMiravo Healthcare™ Obtains Final Order Approving Plan of ArrangementFebruary 24, 2023 | seekingalpha.comMRVFF Nuvo Pharmaceuticals Inc.February 21, 2023 | finance.yahoo.comMiravo Healthcare™ Special Meeting ReminderOctober 31, 2022 | finance.yahoo.comMiravo Healthcare™ Announces Third Quarter 2022 Results Release Date and Conference Call DetailsAugust 2, 2022 | finance.yahoo.comMiravo Healthcare™ Announces Second Quarter 2022 Results Release Date and Conference Call DetailsApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 16, 2022 | finance.yahoo.comMiravo Healthcare™ Announces First Quarter 2022 ResultsMay 12, 2022 | stockhouse.comMiravo Healthcare(TM) Provides an Update on the United States Pennsaid® 2% BusinessMay 12, 2022 | finance.yahoo.comMiravo Healthcare™ Provides an Update on the United States Pennsaid® 2% BusinessMay 2, 2022 | stockhouse.comMiravo Healthcare(TM) Announces First Quarter 2022 Results Release Date and Virtual Annual Meeting of ShareholdersMay 2, 2022 | finance.yahoo.comMiravo Healthcare™ Announces First Quarter 2022 Results Release Date and Virtual Annual Meeting of ShareholdersApril 19, 2022 | finance.yahoo.comMiravo Healthcare™ to Present at Bloom Burton & Co. Healthcare Investor ConferenceMarch 29, 2022 | seekingalpha.comNuvo Pharmaceuticals; reports Q4 resultsMarch 28, 2022 | seekingalpha.comNuvo Pharmaceuticals Inc. 2021 Q4 - Results - Earnings Call PresentationMarch 28, 2022 | finance.yahoo.comMiravo Healthcare™ Announces 2021 and Fourth Quarter ResultsMarch 25, 2022 | stockhouse.comMiravo Healthcare(TM) Acknowledged In The Globe and Mail's Third-Annual Women Lead Here Benchmark of Executive Gender DiversityMarch 14, 2022 | finance.yahoo.comMiravo Healthcare™ Announces Fourth Quarter 2021 Results Release Date and Conference Call DetailsMarch 1, 2022 | finance.yahoo.comMiravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Older*February 28, 2022 | stockhouse.comMiravo Healthcare(TM) Announces Summary Judgment Ruling by the United States District Court for the District of New JerseyFebruary 28, 2022 | finance.yahoo.comMiravo Healthcare™ Announces Summary Judgment Ruling by the United States District Court for the District of New JerseyFebruary 28, 2022 | finance.yahoo.comMiravo Healthcare(TM) to Present at Q1 Virtual Investor SummitJanuary 24, 2022 | finance.yahoo.comMiravo Healthcare™ Named to 2022 OTCQX Best 50January 18, 2022 | stockhouse.comMiravo Healthcare(TM) Announces Participation at the H.C. Wainwright Bioconnect ConferenceJanuary 6, 2022 | finance.yahoo.comMiravo Healthcare™ Announces Participation at the H.C. Wainwright Bioconnect ConferenceSee More Headlines Receive MRVFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:MRVFF CUSIPN/A CIKN/A Webwww.nuvopharmaceuticals.com Phone(905) 673-6980Fax905-673-1842Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,700,000.00 Net Margins20.88% Pretax Margin25.58% Return on Equity-1,996.22% Return on Assets14.25% Debt Debt-to-Equity Ratio9.97 Current Ratio2.11 Quick Ratio1.77 Sales & Book Value Annual Sales$54.98 million Price / Sales0.20 Cash Flow$0.09 per share Price / Cash Flow11.09 Book Value($0.80) per share Price / Book-1.22Miscellaneous Outstanding Shares11,400,000Free Float10,602,000Market Cap$11.17 million OptionableNot Optionable Beta0.98 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesJesse F. LedgerPresident & Chief Executive OfficerBernard ChiassonChief Scientific Officer & VP-OperationsMary-Jane E. BurkettChief Financial Officer & Vice PresidentWade HullVice President-Research & DevelopmentKatina K. LoucaidesSecretary, Vice President & General CounselKey CompetitorsMonopar TherapeuticsNASDAQ:MNPRAntibe TherapeuticsOTCMKTS:ATBPFEterna TherapeuticsNASDAQ:ERNAInhibitor TherapeuticsOTCMKTS:INTIGalera TherapeuticsNASDAQ:GRTXView All Competitors MRVFF Stock Analysis - Frequently Asked Questions How have MRVFF shares performed in 2024? Nuvo Pharmaceuticals' stock was trading at $0.9795 on January 1st, 2024. Since then, MRVFF shares have increased by 0.0% and is now trading at $0.9795. View the best growth stocks for 2024 here. How do I buy shares of Nuvo Pharmaceuticals? Shares of MRVFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MRVFF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvo Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
